- Home
- LSBK vs ACET Comparison
LSBK vs ACET Comparison
Compare LSBK & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSBK
- ACET
- Stock Information
- Founded
- LSBK 1891
- ACET 1947
- Country
- LSBK United States
- ACET United States
- Employees
- LSBK N/A
- ACET N/A
- Industry
- LSBK Savings Institutions
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- LSBK Finance
- ACET Health Care
- Exchange
- LSBK Nasdaq
- ACET Nasdaq
- Market Cap
- LSBK 90.3M
- ACET 70.3M
- IPO Year
- LSBK 2006
- ACET N/A
- Fundamental
- Price
- LSBK $15.97
- ACET $0.72
- Analyst Decision
- LSBK
- ACET Buy
- Analyst Count
- LSBK 0
- ACET 6
- Target Price
- LSBK N/A
- ACET $6.00
- AVG Volume (30 Days)
- LSBK 4.9K
- ACET 324.2K
- Earning Date
- LSBK 04-21-2025
- ACET 03-06-2025
- Dividend Yield
- LSBK 4.51%
- ACET N/A
- EPS Growth
- LSBK 6.97
- ACET N/A
- EPS
- LSBK 0.88
- ACET N/A
- Revenue
- LSBK $25,846,000.00
- ACET N/A
- Revenue This Year
- LSBK N/A
- ACET N/A
- Revenue Next Year
- LSBK N/A
- ACET N/A
- P/E Ratio
- LSBK $18.06
- ACET N/A
- Revenue Growth
- LSBK N/A
- ACET N/A
- 52 Week Low
- LSBK $10.30
- ACET $0.69
- 52 Week High
- LSBK $16.95
- ACET $2.40
- Technical
- Relative Strength Index (RSI)
- LSBK 49.59
- ACET 37.26
- Support Level
- LSBK $15.71
- ACET $0.74
- Resistance Level
- LSBK $16.12
- ACET $0.91
- Average True Range (ATR)
- LSBK 0.26
- ACET 0.06
- MACD
- LSBK -0.05
- ACET -0.00
- Stochastic Oscillator
- LSBK 6.17
- ACET 12.61
About LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and, to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.